What Is BPC-157?
BPC-157 is a synthetic pentadecapeptide, which is a peptide made of 15 amino acids. Scientific studies describe it as a gastric peptide and study it as a distinct peptide compound. The name BPC-157 refers to this specific peptide sequence.
BPC-157 is classified as a gastric pentadecapeptide in peptide research. Its identity comes from its peptide structure and sequence. This makes it different from the larger protein material linked to its original description.
Research Overview Table
Chemical and Molecular Characteristics
BPC-157 is a linear pentadecapeptide consisting of 15 amino acids. Published studies describe the peptide as a partial sequence of the human gastric juice protein BPC. Its molecular weight is approximately 1,419 Da. The sequence contains three consecutive proline residues, which are a notable structural feature of the peptide.
The peptide's chemical properties are related to its amino acid composition and structure. Published research reports that BPC-157 dissolves freely in water at pH 7.0 and in saline. Research also describes the peptide as stable under gastric conditions. This has been studied as part of its chemical behavior.
Certificates:
Mechanism of Action Under Investigation
BPC-157 has no single confirmed mechanism of action. Recent research identified FBXO22 as a direct intracellular binding partner. In this study, BPC-157 interacted with FBXO22 through its third proline residue. The interaction reduced FBXO22-dependent ubiquitination and proteasomal degradation of BACH1, resulting in greater BACH1 protein stability. The BPC-157–FBXO22 interaction was investigated using co-immunoprecipitation, ELISA, and surface plasmon resonance.
Earlier studies investigated BPC-157 in relation to VEGFR2 signaling. Experimental findings showed increased VEGFR2 expression and receptor internalization, followed by activation of the VEGFR2-Akt-eNOS pathway. Separate research examined the Src-Caveolin-1-eNOS pathway, reporting increased phosphorylation of Src, Caveolin-1, and eNOS and changes in nitric oxide generation. These studies describe signaling events observed after BPC-157 exposure rather than a confirmed receptor-mediated mechanism.
The current evidence therefore supports several experimentally studied molecular interactions rather than one established primary target. The recently identified FBXO22-BACH1 interaction provides direct evidence of molecular binding, while the VEGFR2 and eNOS findings show downstream signaling links. How these pathways are connected, whether they work independently or come together, and which interaction is the main molecular event remain unclear.
Scientific Research Context
BPC-157 has accumulated a substantial research literature over more than three decades, but the evidence base remains predominantly preclinical. Published work includes in vitro studies, animal experiments, and a limited number of human studies. Research has progressed from early experimental investigations to more recent efforts to characterize pharmacokinetics, formulation, and human exposure. However, clinical research remains early. With small human studies and no established body of controlled clinical evidence. Overall, the literature is relatively broad in preclinical settings but remains limited in clinical maturity.
BPC-157 Biology and Biological Pathways
Primary Biological Function
BPC-157 has been investigated as a cytoprotective peptide, particularly in studies of gastric mucosal and epithelial integrity. Experimental literature describes its biological activity within the framework of gastric cytoprotection and adaptive cytoprotection.
Relevant Metabolic or Signaling Pathways
BPC-157 has been investigated in relation to VEGFR2-Akt-eNOS, Src-Caveolin-1-eNOS, ERK1/2, and Egr-1/NAB2 signaling. These pathways are involved in endothelial signaling, nitric oxide regulation, and cellular signaling processes. Published studies have examined these pathways in experimental cell and tissue models.
Tissue-Specific Biology
BPC-157 research includes gastrointestinal, musculoskeletal, vascular, and skin tissues. Gastrointestinal studies include gastric and intestinal tissue, while musculoskeletal research includes tendon, ligament, skeletal muscle, and bone. Vascular studies include endothelial tissue and skin tissue. Researchers have examined skin tissue in experimental models.
Experimental Biomarkers
Published BPC-157 studies have examined VEGF, VEGFR2, eNOS, ERK1/2, Egr-1, CD34, and von Willebrand factor (FVIII). These markers have been measured in experimental studies of vascular, endothelial, muscle, tendon, and skin tissues. The specific markers used vary with the biological system and experimental model.
Laboratory Investigation Methods
BPC-157 has been studied using cell culture, tissue histology, immunohistochemistry, gene-expression analysis, and protein-expression assays. Experimental studies have also used cell migration, proliferation, tube-formation, and nitric oxide assays to examine cellular responses. These methods provide laboratory approaches for examining BPC-157 at the cellular, molecular, and tissue levels.
Experimental Models Used in Published Research
Published BPC-157 research includes cell-based models, ex vivo tissue models, and in vivo animal models. The literature includes cultured cells, tendon explants, and mainly rodent models. Each model provides a different level of biological complexity, while limitations arise from the absence of whole-organism conditions in isolated models and species differences in animal models.
Cell Culture Models
Cultured endothelial cells and tendon fibroblasts have been used as in vitro models. Their main limitation is that isolated cells lack intact tissue structure and systemic interactions. Findings from these models therefore cannot fully represent the biological environment of a living organism.
Ex Vivo Tissue Models
Tendon explants have been used as an ex vivo model for BPC-157. Tendon tissue maintained under controlled culture conditions. The model retains native tissue structure while allowing direct study of the tissue outside an intact organism. Its main limitation is the absence of normal circulation and systemic interactions present in vivo.
Rodent Models
Rat models make up a large part of the animal research on BPC-157. Studies use different experimental injury models. Their main limitation is that rodent anatomy, physiology, metabolism, and tissue responses differ from those in humans. This limits how directly animal findings can be applied to humans.
BPC-157 Published Scientific Research
Gastrointestinal Research
BPC-157 has been studied extensively in gastrointestinal research, particularly in gastric and intestinal injury models. Published work has examined gastric mucosal integrity, gastrointestinal lesions, intestinal tissue, and different forms of experimentally induced gastrointestinal injury. This represents one of the earliest and most developed areas of BPC-157 research.
Musculoskeletal Research
A substantial body of research has examined BPC-157 in tendon, ligament, skeletal muscle, bone, and muscle-to-bone junctions. Studies include experimental models of Achilles tendon injury, ligament injury, skeletal muscle injury, fracture, and surgical muscle detachment. The literature has also examined tendon explants and cultured tendon fibroblasts.
Vascular and Endothelial Research
Research on BPC-157 has examined angiogenesis, endothelial function, vascular tone, vasomotor responses, and blood-vessel biology. Studies have also investigated vascular responses associated with nitric oxide signaling and VEGFR2 expression. More recent work has examined vascular reactivity in isolated human internal mammary artery tissue.
Skin and Tissue Repair Research
Published BPC-157 research has examined incisional and excisional skin wounds, deep burns, alkali burns, and CO₂-laser skin injuries. Researchers have also examined wound healing at connected tissue sites, including colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, and rectovaginal wounds.
Nervous System Research
BPC-157 has been examined in central and peripheral nervous system models, including experimental research involving neural injury and nervous system signaling. The published literature in this area is smaller than the gastrointestinal and musculoskeletal literature and remains predominantly preclinical.
Human Research
Published human research on BPC-157 has examined intra-articular administration in people with knee pain. It has also examined intravesical administration in patients with interstitial cystitis. More recent research has investigated intravenous administration and pharmacokinetics in healthy adults.
Limitations of Current Research
Evidence Is Predominantly Preclinical
Most published research on BPC-157 comes from animal and laboratory studies. Human research represents a much smaller part of the available literature, with only a few published human studies identified in recent reviews. The current evidence base is therefore weighted strongly toward preclinical research rather than human clinical research.
Human Clinical Evidence
Human research on BPC-157 remains limited. Published studies have examined knee pain, interstitial cystitis, ulcerative colitis, and intravenous exposure and pharmacokinetics. Most studies involved small numbers of participants, and the available human literature is still much smaller than the preclinical literature.
Species Differences
Most BPC-157 research comes from animal models, so differences between animal and human biology remain an important limitation. Species differences in pharmacokinetics, metabolism, tissue biology, and physiological responses can affect how experimental findings translate to humans. Animal findings therefore cannot be assumed to reflect human responses.
Study Design Limitations
BPC-157 studies use varied experimental designs, models, routes of administration, and study protocols. The human literature also includes small pilot and retrospective studies rather than large controlled trials. These differences make the available evidence difficult to compare directly and limit how confidently researchers can combine results from separate studies.
Independent Replication
Independent replication remains limited in parts of the BPC-157 literature. A review of the musculoskeletal evidence noted that only a small number of research groups had conducted detailed investigations over the preceding two decades. Additional studies from independent laboratories would help determine whether reported findings are reproducible.
Long-Term Evidence
Long-term human evidence for BPC-157 is still lacking. Animal studies have included repeated dosing for several days, and a 28-day repeat-dose study has been reported in rats and dogs. However, these studies do not show what prolonged exposure may mean in humans. Longer-term human studies have not yet established this part of the evidence base.
Analytical Documentation
Analytical documentation provides the chemical data needed to confirm the identity and characterize BPC-157. HPLC separates the peptide from related substances and can be used to assess chromatographic purity. LC-MS provides mass-based confirmation of the peptide and can help identify related peptide species. Published BPC-157 studies have used chromatographic and mass-spectrometric methods for chemical characterization.
NMR can provide structural information for peptide characterization, but it is not necessary for every BPC-157 analysis. A Certificate of Analysis (COA) records batch-specific test results, such as identity and purity, for a particular lot. These records are useful when verifying the material used in laboratory work. Analytical documentation verifies product identity and quality rather than biological performance.
Storage and Laboratory Handling
BPC-157 should be handled only by qualified laboratory staff following approved laboratory techniques. Store material as per the product specification and the batch documentation accompanying the material to maintain the sample integrity.
Always keep containers well sealed while not in use. Use clean equipment to limit the chance of contamination or degradation of the sample. BPC-157 is supplied exclusively for laboratory research and is not intended for human or veterinary use.
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.